BioSpace News Archive

Brainlab announced today that the company has reached two major milestones with the FDA clearance for both Loop-X ® Mobile Imaging Robot and Cirq ® , a robotic surgical system. Following on CE mark approvals last summer, the FDA clearance paves the way for Brainlab to now enter the US markets with the Cirq robotic alignment module for spine procedures, and Loop-X

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences.

Nephros , Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it will file its fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after market close and will host a conference call that same day at 4:30 PM ET

-Biohaven’s proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19 -BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced that the Company will participate in the following virtual investor conferences.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in March. Cowen 41 st Annual Virtual Health Care Conference

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the initiation of Phase 2 of the company’s two-phase effort to expand the overall manufacturing capacity within its Myford facility.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in March

ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults. If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the 7 th Annual Immuno-Oncology 360° Conference on February 25, 2021